Anlotinib enhances the sensitivity to docetaxel in lung cancer through inhibiting DDR1-mediated glycolytic pathway
Xueqin Chen, Juan Shen, Zhifei Xu, Bo Xu, Jie Huang, Jingjing Jiang, Yidan Chen, Xin Li, Shaoyu Yang, Kan Wu, Jiaoli Wang, Peihua Luo, Qiaojun He, Shenglin Ma, Bing Xia, Bo Yang · 2026
Read Anlotinib enhances the sensitivity to docetaxel in lung cancer through inhibiting DDR1-mediated glycolytic pathway by Xueqin Chen, Juan Shen, Zhifei Xu, Bo Xu, Jie Huang, Jingjing Jiang, Yidan Chen, Xin Li, Shaoyu Yang, Kan Wu, Jiaoli Wang, Peihua Luo, Qiaojun He, Shenglin Ma, Bing Xia, Bo Yang (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13617657.txt.
Description
Xueqin Chen and co-authors pair two cancer drugs to beat resistance in lung cancer. Their 2026 study centers on a receptor called DDR1, which helps tumor cells grow, spread, and resist drugs. High levels of the active receptor tied to poor outcomes and weak response to a standard drug.
A drug screen found that anlotinib, a pill that blocks growth signals, strongly curbs the receptor. Adding it made cancer cells and tumors in mice far more open to the standard drug. The boost vanished in cells with the receptor gene removed. The pair works by cutting a sugar-burning path the receptor drives. A trial arm showed higher response rates and longer control than past data.
Catalog record
| CREATOR | Xueqin Chen, Juan Shen, Zhifei Xu, Bo Xu, Jie Huang, Jingjing Jiang, Yidan Chen, Xin Li, Shaoyu Yang, Kan Wu, Jiaoli Wang, Peihua Luo, Qiaojun He, Shenglin Ma, Bing Xia, Bo Yang |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 61 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |